HRTX - 2 Short-Squeeze Candidates That Could Go Parabolic Soon
Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon.
The mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.
Last month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's specialist Cortexyme (NASDAQ: CRTX) and the commercial-stage biotech Heron Therapeutics (NASDAQ: HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.
For further details see:
2 Short-Squeeze Candidates That Could Go Parabolic Soon